Exploratory Efficacy of INP104 in Migraine Patients By Prior Treatment
Synopsis
Results suggest that INP104 may be an effective acute treatment option for migraine regardless of prior acute treatment, which includes triptans.
Disclosures
Tanya R. Bilchik has participated in speaker bureaus for AbbVie, Amgen/Allergan, Biohaven Pharmaceuticals, Eli Lilly, Impel Pharmaceuticals, and Teva Pharmaceuticals. Robert Vann, Sutapa Ray, Stephen B. Shrewsbury, and Sheena K. Aurora are full-time employees of Impel Pharmaceuticals and are stockholders in Impel Pharmaceuticals. Stephen B. Shrewsbury is an officer of Impel Pharmaceuticals.
Author(s):
- Sutapa Ray, PhD, Medical Affairs, Impel Pharmaceuticals
- Tanya R. Bilchik, Neurologist, Yale University School of Medicine
- Robert Vann, Medical Affairs, Impel Pharmaceuticals
- Stephen B. Shrewsbury, CMO, Impel Pharmaceuticals
- Dr. Sheena Aurora, MD, Medical Affairs, Impel Pharmaceuticals
| Display Label | Action |
|---|---|
| 36_IMPEL_~1 | Download Handout |
| NPC 2022 Poster_STOP 301 Acute Treatment History image | Download Resource |